Related Experiment Video
Updated: Jul 23, 2026

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders
Published on: August 18, 2016
[Valvular heart disease associated with ergotamine]
Efrén Martínez Quintana1, Rafael Llorens León, Elena Redondo Martínez
1Servicio de Cardiología, Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain. efrenmq@eresmas.com
Ergotamine can prevent migraines but may cause adverse reactions. Long-term use in two patients was linked to the development of heart valve disorders, a less common side effect.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Ergotamine is a medication primarily used for migraine treatment.
- Common side effects include nausea, vomiting, myalgia, diarrhea, and dry mouth.
- Contraindications involve peripheral vascular disease and liver disease due to its vasospastic and metabolic properties, respectively.
Observation:
- The cardiac effects of ergotamine are less frequently documented.
- Two patients undergoing long-term ergotamine therapy presented with valvular disorders.
Findings:
- Long-term ergotamine use may be associated with the development of cardiac valvular disorders.
- This suggests a potential underrecognized adverse effect of chronic ergotamine treatment.
Implications:
- Clinicians should consider monitoring cardiac health in patients on long-term ergotamine.
- Further research is warranted to elucidate the mechanism and prevalence of ergotamine-induced valvular disease.
More Related Videos
08:34Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
Published on: November 18, 2018
08:56Detection of Regulated Ergot Alkaloids in Food Matrices by Liquid Chromatography-Trapped Ion Mobility Spectrometry-Time-of-Flight Mass Spectrometry
Published on: November 22, 2024
Related Concept Videos
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Heart Failure Drugs: Inotropic Agents
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: β-Blockers
Mitral Valve Prolapse II: Assessment and Management
Mitral Regurgitation I: Introduction